For most people, yes — with some care. NIH's HIV treatment guidelines state plainly that ongoing alcohol use is not a contraindication to antiretroviral therapy. The bigger risks are missed doses on drinking days and liver strain — and if you have liver disease or active hepatitis C, the guidance is not to drink at all. Be honest with your provider; guidelines tell them to be nonjudgmental.
There is no alcohol ban in HIV treatment
The NIH adult and adolescent antiretroviral guidelines are explicit: "ongoing substance use is not a contraindication to antiretroviral therapy (ART)," people who use substances "can achieve and maintain viral suppression with ART," and "ongoing alcohol use is not a contraindication for a person to receive ART"[1]. Nobody should be denied treatment, or deny themselves treatment, because they drink.
Drinking is also common among people living with HIV. NIH cites recent estimates that more than 50% of people with HIV in the United States consume some alcohol (range 54%–67%), and that 27% screened positive for unhealthy alcohol use across seven U.S. university-based HIV clinics[1]. The guidelines recommend that alcohol and substance-use screening be part of routine HIV care, with treatment offered as part of comprehensive care, and they direct clinicians to be "nonjudgmental when addressing substance use with people with HIV"[1]. A widely used clinical review suggests screening everyone at intake, repeating annually if negative and at every visit if positive[4].
Adherence is the real concern
The strongest evidence link is behavioral, not chemical. NIH guidelines report studies showing "both temporal and dose-related relationships between alcohol use and adherence," with ART "more likely to be missed on a given drinking day and the day after drinking," and a stronger association on heavy or binge drinking days[1]. Unhealthy alcohol use has been associated with interruptions across the HIV care continuum: lower ART adherence, loss of durable viral suppression, higher risk of viral rebound, lower retention in care, and increased mortality[1].
Part of the mechanism is a myth people carry with them. NIH names "patient perceptions of adverse interactions between alcohol and ARV drugs" as one driver of skipped doses[1] — people skip a pill because they had a drink, when the guidance is the opposite. The guidelines conclude that adherence counseling "should highlight the benefits of ART use, irrespective of concurrent substance use"[1]. HIV.gov makes the same point in plainer words: alcohol and drug use can cause people to forget doses and appointments, and missing doses lets HIV multiply[2]. If you drank, still take your dose.
Liver health and hepatitis co-infection: where the advice gets firm
This is the one place the guidance stops being flexible. NIH states that unhealthy alcohol use alone, and in combination with viral hepatitis co-infection, "can hasten liver fibrosis progression in people with HIV," and that "individuals with liver disease, including active HCV infection, should not consume alcohol"[1]. The same section notes that cirrhosis — from alcohol, viral hepatitis, or metabolic dysfunction–associated steatotic liver disease — "can result in altered metabolism of ARV drugs," with dosing adjusted by Child-Pugh classification, and that regimens with low hepatotoxicity and low drug-interaction potential are preferred for people with substance use disorders[1].
HIV.gov adds that alcohol misuse is dangerous for people with hepatitis B, hepatitis C, or other liver disease: it can make a person get sick faster and can worsen hepatitis treatment side effects[2]. A clinical review lists the situations where the recommendation is abstinence rather than cutting back: alcohol dependence, pregnancy, HCV infection or another condition where alcohol is not recommended, medications that interact with alcohol, blackouts, and repeated failure to cut back[4]. Support is part of HIV care, not a referral out of it: NIH notes behavioral treatment produces a small but significant reduction in alcohol use among people with HIV, and that pharmacotherapy for alcohol use disorder should be offered as part of HIV care[1].
Two interactions people ask about: abacavir and metronidazole
Abacavir. A phase I crossover study in 24–25 men living with HIV found that ethanol increased plasma abacavir exposure — AUC∞ rose 41% (11.07 to 15.62 µg·h/mL), Cmax rose 15%, and terminal half-life rose 26% (1.42 to 1.79 hours)[5]. Two reassurances came from the same study: a single 600-mg dose of abacavir did not alter blood ethanol concentration, and "there were no disulfiram-type reactions in any subject who received coadministration of abacavir and ethanol"[5]. So the documented effect is modestly higher abacavir levels — context, not alarm. Worth a conversation with your provider if you drink heavily. Note that this study enrolled men only, and abacavir is less common in current first-line regimens[5].
Metronidazole. If you are treated with metronidazole for an infection, package labeling recommends against alcohol during treatment and for 48 hours afterward because of disulfiram-like reaction risk, and major pharmacy chains advise avoiding alcohol for up to 72 hours[6]. The evidence behind that warning is genuinely contested: a systematic review concluded that "data are controversial regarding risk of a disulfiram-like reaction" and that "despite the widespread belief that metronidazole is contraindicated with alcohol consumption, the literature raises doubt"[6]. Practical framing: follow the label, and ask your pharmacist about your specific prescription.
What "moderate" actually means
Numbers beat vibes. HIV.gov defines one standard drink as a 12-ounce beer, a 5-ounce glass of wine, or a shot of liquor. Binge drinking means reaching a blood alcohol concentration of 0.08% or higher — about 4 drinks in 2 hours for women, 5 for men. Heavy drinking means more than 3 drinks a day or 7 a week for women, more than 4 a day or 14 a week for men[2]. HIV.gov also notes that for people under 21 and people who are pregnant, any alcohol use is considered misuse[2].
CDC does not sell moderate drinking as healthy. The Dietary Guidelines for Americans recommends adults of legal drinking age either not drink or drink in moderation, and CDC notes that "even moderate drinking may increase your risk of death and other alcohol-related harms, compared to not drinking," including that even less than one drink per day can raise the risk of certain cancers[3]. CDC also lists people taking medications that can interact with alcohol, and people with certain liver diseases, among those who should not drink at all[3]. Bring your actual drinking to your next appointment — including the awkward parts. That conversation is how the plan gets built around your real life.
Related questions
Will one drink make my HIV medicine stop working?
No. NIH guidelines state that ongoing alcohol use is not a contraindication to antiretroviral therapy, and that people who use substances can achieve and maintain viral suppression. The documented risk comes from missed doses, not from a single drink.
Should I skip my dose if I've been drinking?
No — skipping is the actual danger. NIH identifies patient perceptions of adverse alcohol–ARV interactions as one reason doses get missed, and advises counseling that emphasizes taking ART regardless of concurrent substance use.
I have hepatitis C. Is alcohol different for me?
Yes. NIH states that individuals with liver disease, including active HCV infection, should not consume alcohol, because unhealthy alcohol use can hasten liver fibrosis progression. HIV.gov adds that alcohol misuse can make a person get sick faster and worsen hepatitis treatment side effects.
Will my provider judge me if I'm honest about drinking?
They are instructed not to. NIH guidelines direct providers to be nonjudgmental when addressing substance use with people with HIV, to screen routinely, and to offer treatment and support as part of comprehensive HIV care.
Related from RiseUpToHIV
References & Sources
- NIH — Substance Use Disorders and HIV (Adult and Adolescent ARV Guidelines). Primary source: alcohol is not a contraindication to ART; adherence, liver, screening, and treatment guidance. ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩ ↩
- HIV.gov — Alcohol, Substance Use, and HIV. Standard-drink, binge, and heavy-drinking definitions, plus hepatitis and liver-disease cautions. ↩ ↩ ↩ ↩
- CDC — Moderate Alcohol Use. Dietary Guidelines framing and CDC's caution that even moderate drinking carries risk. ↩ ↩
- Addressing Alcohol Use in People With HIV (PMC). Clinical review: screening intervals and the situations where abstinence, not moderation, is advised. ↩ ↩
- McDowell et al. — Pharmacokinetic Interaction of Abacavir and Ethanol (PMC). Phase I crossover study: abacavir AUC +41% with ethanol; no disulfiram-type reactions; men only. ↩ ↩ ↩
- Mergenhagen et al. — Fact versus Fiction: Alcohol and Antibiotic Interactions (PMC). Metronidazole labeling guidance alongside the review's finding that the disulfiram-like reaction evidence is contested. ↩ ↩
Community publications like POZ, Positively Aware, and TheBody inform framing and lived-experience context on RiseUpToHIV. Every clinical, epidemiological, or public-health claim above is anchored to a primary source.